Maralixibat Chloride

氯马昔巴特

Report date: 2026/04/20 20:01:59
NME

Base Information

Drug NameMaralixibat Chloride
Drug Alias NameMaralixibat chloride马昔巴特MaralixibatLopixibat chlorideLopixibat +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIleal bile acid transporter inhibitors
TargetsIleal bile acid transporter
Therapy Area/IndicationsProgressive familial intrahepatic cholestasisPruritusLiver Diseases +[9] 
Global Approved IndicationsAlagille Syndrome
Approved Indications in ChinaAlagille Syndrome
Original Approved Country/TerritoryUnited States
Original Approved Date2021/09/29
Country/TerritoryBelgiumCanadaUnited States +[26] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesMirum PharmaceuticalsGC Biopharma CorpMirum Pharmaceuticals Inc +[7] 
Inactive CompaniesHalo Pharmaceutical Canada IncBeihai Kangcheng (Beijing) Pharmaceutical Technology Co LtdSyneos Health（Beijing）Inc Ltd
Active IndicationsProgressive familial intrahepatic cholestasisPruritusLiver Diseases +[7] 
Inactive IndicationsCholangitis, SclerosingLiver Cirrhosis, Biliary

Other Information

ATC CodeA05AX
Related LinksWikipediaDrugBankKEGG